PRESENTATION · Sep 2025 · PDF
Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
PRESENTATION · Dec 2024 · PDF
Infigratinib - ISDS 2024 - Clinical Development Program Update
PRESENTATION · Dec 2024 · PDF
BBIO - Infigratinib - PROPEL 2 Data Update and ACCEL Program Initiation
PRESENTATION · Dec 2023 · PDF
Infigratinib - ESPE 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study
PRESENTATION · Dec 2023 · PDF
Infigratinib - ENDO 2023 - Updated Six Month Results in Phase 2 Cohort 5 Study
PRESENTATION · Dec 2023 · PDF
Infigratinib - ENDO 2023 - Murine Models in Achondroplasia and Hypochondroplasia
PRESENTATION · Dec 2023 · PDF
Infigratinib - ENDO 2023 - PROPEL, PROPEL 2 and PROPEL OLE
PRESENTATION · Dec 2023 · PDF
Infigratinib - ENDO 2023 -Evaluation of Bone Mineral Density
PRESENTATION · Dec 2023 · PDF